Alanine transaminase

There are 99 papers on alanine transaminase in aging research: 23 trials and 45 observational studies in people, 21 in animals, 7 reviews. The newest story, Oct 8, 2026: “Bands reduced liver fat in postmenopausal women with MASLD”.

Biomarker

99 papers study it34 more mention it32 findings

MeSH

4 new papers in 30 daysSee all 133 papers on alanine transaminase

“0.02% (95% CI: 0.004-0.035) higher alanine transaminase”
Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trialGeroScience2025doi:10.1007/s11357-025-01968-0
  • Human trial23
  • Humans45
  • Animals21

Interventions

17

Levocarnitine

downin humans2

2 studies
  1. Levocarnitine decreases alanine transaminase in humans.

    “At the end of week 8, a significant reduction from baseline in alanine aminotransferase (ALT) was observed in the l‐carnitine group (p: 0.043), while no significant change was observed in the control group.”

    Human trial2 months

    Effects of l-carnitine on frailty status in patients with liver cirrhosis: A randomized-controlled trial

    Health science reports

  2. Levocarnitine decreases alanine transaminase in humans (liver cirrhosis) (p: 0.043).

    “L-carnitine administration resulted in a significant decrease in alanine transaminase levels (p: 0.043)”

    Human trialliver cirrhosis500 mg orally three times a day8 weeksn = 77

    Effects of l-carnitine on frailty status in patients with liver cirrhosis: A randomized-controlled trial

    Health science reports

  3. Levocarnitine decreases alanine transaminase in humans (compared to placebo) (p < 0.001).

    “L-carnitine supplementation reduced ALT levels in overweight and normal BMI subjects at any trial dose and trial duration ≥ 12 weeks and reduced AST levels in overweight subjects and trial dose ≥ 2 g/day.”

    Reviewcompared to placebo

    The effects of L-carnitine supplementation on inflammatory and anti-inflammatory markers in adults: a systematic review and dose-response meta-analysis

    Inflammopharmacology

More on Levocarnitine

Atorvastatin

upin humans1

1 study
  1. Atorvastatin increases alanine transaminase in humans.

    “The change in ALT levels from baseline was higher in the atorvastatin group compared with the placebo group at 4 weeks (p = 0.001), 12 (p = 0.03) and 24 (p = 0.03) months.”

    Human trial2-yearn = 304

    Effect of atorvastatin on skeletal muscles of patients with knee osteoarthritis: Post-hoc analysis of a randomised controlled trial

    Frontiers in medicine

  2. Atorvastatin increases alanine transaminase in humans (knee osteoarthritis) (median 26 vs. 21, p = 0.004).

    “The atorvastatin group had higher ALT than placebo group at 1 (median 26 vs. 21, p = 0.004) and 6 (25 vs. 22, p = 0.007) months”

    Human trialknee osteoarthritis40 mg daily1 month

    Effect of atorvastatin on skeletal muscles of patients with knee osteoarthritis: Post-hoc analysis of a randomised controlled trial

    Frontiers in medicine

More on Atorvastatin

Nicotinamide

downin humans1

1 study
  1. Nicotinamide decreases alanine transaminase in humans (−26.6% vs −0.74%).

    “Despite the nonsignificant difference in ALT and AST between groups at baseline and after 12 weeks, the within-group comparisons revealed significant changes (p < 0.001) in the nicotinamide group only with the median percent change, in ALT and AST, respectively, −26.6% and −13.3% in the nicotinamide group versus −0.74% and 2.48% in the control group, respectively”

    Human trial12 weeksn = 70

    Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial

    Therapeutic advances in chronic disease

  2. Nicotinamide decreases alanine transaminase in humans (diabetic NAFLD patients) (-26.6% vs -0.74%).

    “significant reduction was observed in liver enzymes with a median decrease in alanine transaminase of 26.6% versus 0.74% in nicotinamide and control groups, respectively.”

    Human trialdiabetic NAFLD patients1000 mg once daily12 weeksn = 61

    Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial

    Therapeutic advances in chronic disease

More on Nicotinamide

Multivitamin

upin humans1RR 1.44

1 study
  1. Multivitamin increases alanine transaminase in humans (IRR, 1.44; 95% CI, 1.11–1.87).

    “The incidence of ALT above the upper level of normal was significantly greater among patients in the high-dose supplementation group than the standard-dose supplementation group (1239 events per 1215 person-years vs 879 events per 1236 person-years; IRR, 1.44; 95% CI, 1.11–1.87).”

    Human trialhigh-dose vs standard-doseminimum of 24 monthsn = 3,418

    Effect of high-dose vs standard-dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial

    JAMA

  2. Multivitamin increases alanine transaminase in humans (initiating HAART) (RR, 1.44; 95% CI, 1.11-1.87).

    “increased the risk of ALT elevations (1239 events per 1215 person-years vs 879 events per 1236 person-years; RR, 1.44; 95% CI, 1.11-1.87) vs standard-dose supplementation.”

    Human trialinitiating HAARToral supplementshigh-dose vs standard-dosemedian follow-up, 15 monthsn = 3,418

    Effect of high-dose vs standard-dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial

    JAMA

More on Multivitamin

Tirzepatide

downin humans1

1 study
  1. Tirzepatide is linked with lower alanine transaminase in humans.

    “alanine transaminase and low-density lipoprotein cholesterol were decreased significantly”

    Humansaverage 4.5 ± 1.0 mg/week24 weeksn = 88

    Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study

    Endocrine journal

More on Tirzepatide

Moderate-intensity intermittent walking

downin humans1

1 study
  1. Moderate-intensity intermittent walking decreases alanine transaminase in humans (sedentary postmenopausal women with obesity) (p = 0.002, d = 0.29).

    “Significant improvements were observed in the TG group in liver enzymes alanine-transaminase (ALT), (p = 0.002, d = 0.29)”

    Human trialsedentary postmenopausal women with obesityMIWT protocol (4 sessions/week, ~85 min/session)10-weekfemalesn = 36

    Moderate-Intensity Intermittent Walking Improves Liver-Related Biomarkers and Reduces Inflammation in Postmenopausal Women With Obesity: A Randomized Controlled Study

    European journal of sport science

More on Moderate-intensity intermittent walking

Carvacrol

downin rats1

1 study
  1. Carvacrol decreases alanine transaminase in rats (versus aged control rats).

    “Carvacrol decreased ALT and AST levels in the serum of aged rats versus aged control rats.”

    Animalsversus aged control ratsoralserum15 or 30 mg/kg60 daysmales

    Protective Effect of Carvacrol against Oxidative Damage in Aged Rats

    Central nervous system agents in medicinal chemistry

More on Carvacrol

Berberine

downin humans1

1 study
  1. Berberine decreases alanine transaminase in humans (MAFLD) (p=0.0105).

    “the BBR group demonstrated a statistically significant decrease in alanine transaminase (ALT) p=0.0105”

    Human trialMAFLDoral1500 mg/day12 weeksn = 70

    Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial

    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society

More on Berberine

Curcumin + piperine

downin humans1

1 study
  1. Curcumin + piperine decreases alanine transaminase in NAFLD patients with moderate-to-high hepatic steatosis (p = 0.007).

    “alanine transaminase (p = 0.007) and aspartate transaminase (p = 0.012) compared with placebo”

    Human trialin NAFLD patients with moderate-to-high hepatic steatosis500 mg/day curcumin plus 5 mg/day piperine12 weeks

    Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: A double-blind, randomized, placebo-controlled clinical trial

    Phytotherapy research : PTR

More on Curcumin + piperine

Wine

downin humans1

1 study
  1. Wine is linked with lower alanine transaminase in humans (compared to that of the nondrinkers).

    “Moderate wine drinking showed a significant alanine transaminase (ALT)- and aspartate aminotransferase-lowering effect compared to that of the nondrinkers.”

    Humanscompared to that of the nondrinkerswinemoderate

    Alcohol consumption and hepatocellular carcinoma: novel insights from a prospective cohort study and nonlinear Mendelian randomization analysis

    BMC medicine

More on Wine

Resveratrol

no changein humans1

1 study
  1. Resveratrol showed no clear effect on alanine transaminase in humans (overweight patients with transaminasemia and histological NAFLD) (p = 0.51).

    “Resveratrol treatment was generally not superior to placebo in improving plasma markers of liver injury (primary outcome: alanine transaminase, p = 0.51).”

    Human trialoverweight patients with transaminasemia and histological NAFLDliver1.5 g daily6 monthsn = 28

    Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

    Scandinavian journal of gastroenterology

More on Resveratrol

Taurine

downin humans1

1 study
  1. Taurine decreases alanine transaminase in chronic alcoholic patients.

    “the AST and ALT activities and levels of cholesterol, triglyceride (TG), bilirubin, and thiobarbituric acid reactive substances (TBARS) of serum plasma in the taurine group were all decreased”

    Human trialin chronic alcoholic patientsliver6 g per day2 or 3 months

    Effect of taurine in chronic alcoholic patients

    Food & function

More on Taurine

All 17

Effects

1

Diabetes mellitus

mediatesin humans1

1 study
  1. Alanine transaminase is linked with diabetes mellitus in humans (causal mediation analysis of the iron overload–diabetes association).

    “CMA showed that liver injury (alanine transaminase) and lipid metabolism abnormalities (triglyceride, apolipoprotein B) contributed to the association between IO and diabetes.”

    Humanscausal mediation analysis of the iron overload–diabetes associationlivern = 5,779

    Iron Overload and the Risk of Diabetes in the General Population: Results of the Chinese Health and Nutrition Survey Cohort Study

    Diabetes & metabolism journal

More on Diabetes mellitus

Upstream

1

Age

downin humans1

1 study
  1. Age is linked with lower alanine transaminase in individuals with obesity (p<.001).

    “ALT elevation is inversely dependent upon age”

    Humansin individuals with obesityn = 328

    The Prevalence of Steatohepatitis Declines with Age in Non-urban Individuals with Obesity

    International Journal of Gastroenterology

Associations

8

Body fat percentage

upin humans1

1 study
  1. Body fat percentage is associated with alanine transaminase in humans (β = 1.06 per % PBF).

    “PBF was significantly associated with alanine transaminase (β = 1.06 per % PBF)”

    Humans

    Association between body fat percentage and metabolic and hematologic biomarkers in Korean adults

    The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

More on Body fat percentage

FABP4

upin humans1

1 study
  1. Alanine transaminase is associated with FABP4 in humans (ρ=0.234, P=0.001).

    “ALT and FABP4 were positively correlated (ρ=0.234, P=0.001).”

    Humansblood

    Comparative cross-sectional study between conventional and IQOS smoking and impact on fatty acid-binding protein 4

    Biomedical reports

More on FABP4

Heated tobacco smoking

upin humans1

1 study
  1. Heated tobacco smoking is associated with alanine transaminase in humans (Compared with non-smokers and conventional cigarette smokers).

    “ALT levels were significantly higher in IQOS smokers compared with both non-smokers (P<0.0001) and cigarette smokers (P=0.001).”

    HumansCompared with non-smokers and conventional cigarette smokersblood

    Comparative cross-sectional study between conventional and IQOS smoking and impact on fatty acid-binding protein 4

    Biomedical reports

More on Heated tobacco smoking

Nicotinamide adenine dinucleotide

upin humans1

1 study
  1. Nicotinamide adenine dinucleotide is associated with alanine transaminase in humans (baseline NAD level, per 1 nM) (0.02% per 1 nM (95% CI 0.004-0.035)).

    “0.02% (95% CI: 0.004-0.035) higher alanine transaminase”

    Human trialbaseline NAD level, per 1 nMbloodn = 80

    Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial

    GeroScience

More on Nicotinamide adenine dinucleotide

Congestive heart failure

upin humans1OR 1.95

1 study
  1. Alanine transaminase is associated with congestive heart failure in humans (post COVID-19) (OR 1.95, 95% CI 1.03-2.53).

    “pre-morbid low ALT remained significantly associated with the occurrence of post COVID-19 CHF (OR-1.95, 95% CI -1.03 to 2.53)”

    Humanspost COVID-19

    Low ALT levels and a new diagnosis of congestive heart failure following COVID-19 infection

    Frontiers in cardiovascular medicine

More on Congestive heart failure

Cortical and subcortical brain structure

mixedin humans1

1 study
  1. Alanine transaminase is associated with cortical and subcortical brain structure in humans.

    “changes in ALT, GGT, AST to ALT ratio, and ALD were significantly associated with altered cortical and subcortical regions”

    HumansBrain

    Associations of liver dysfunction with incident dementia, cognition, and brain structure: A prospective cohort study of 431 699 adults

    Journal of neurochemistry

Mortality

upin humans1HR 1.25

1 study
  1. Alanine transaminase is associated with mortality in humans (myelodysplastic syndrome) (HR = 1.25, 95% CI: 1.01-1.56, P = .041).

    “A multivariate model controlling for age, sex, body mass index, hemoglobin and albumin concentrations, and low ALT levels was still significantly associated with increased mortality”

    Humansmyelodysplastic syndrome<12 IU/Ln = 831

    Low ALT, a marker of sarcopenia and frailty, is associated with shortened survival amongst myelodysplastic syndrome patients: A retrospective study

    Medicine

Hepatocellular carcinoma

upin humans1HR 6.8

1 study
  1. Alanine transaminase is linked with a higher risk of hepatocellular carcinoma in humans (HR 6.80, 95% CI 3.00-15.42; p < 0.001).

    “elevated ALT was independently associated with an increased HCC risk”

    Humanselevated serum levels, adjusted for age, gender, comorbidities, statin, metformin and aspirin use

    The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease

    International journal of cancer

More on Hepatocellular carcinoma

Latest

Dec 2025: 3Jan 2026: 7Feb 2026: 6Mar 2026: 3Apr 2026: 2May 2026: 0Jun 2026: 0Jul 2026: 2Aug 2026: 1Sep 2026: 3Oct 2026: 1Nov 2026: 129 papers in 12 months
Journal of Science and Medicine in Sport

Bands reduced liver fat in postmenopausal women with MASLD

In postmenopausal women with metabolic dysfunction-associated steatotic liver disease, an eight-week elastic band workout reduced a liver fat measure by 36.77 dB/m…In postmenopausal women with metabolic dysfunction-associated steatotic liver disease, an eight-week elastic band workout reduced a liver fat measure by 36.77 dB/m against controls.

See all 133 papers on alanine transaminase